🇺🇸 FDA
Pipeline program

CD123 targeted CAR-NK cells

PBC050

Phase 2 mab active

Quick answer

CD123 targeted CAR-NK cells for Acute Myeloid Leukemia is a Phase 2 program (mab) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
PRECISION BIOSCIENCES INC
Indication
Acute Myeloid Leukemia
Phase
Phase 2
Modality
mab
Status
active

Clinical trials